表紙
市場調查報告書

關注市場分析:纖維肌痛症

Market Spotlight: Fibromyalgia

出版商 Datamonitor Healthcare 商品編碼 912154
出版日期 內容資訊 英文 37 Pages
商品交期: 最快1-2個工作天內
價格
關注市場分析:纖維肌痛症 Market Spotlight: Fibromyalgia
出版日期: 2019年11月28日內容資訊: 英文 37 Pages
簡介

本報告提供全球纖維肌痛症市場相關調查,疾病的背景、概要,治療方法,開發平台治療藥概要,臨床試驗狀況等資料彙整。

概要

要點

疾病的背景

  • 疾病定義
  • 症狀
  • 患者的亞型
  • 風險因素
  • 診斷

治療

  • 藥物治療

流行病學

  • 盛行率

已上市藥物

開發平台藥物

近幾年的活動、分析師的意見

  • 複數的藥物
  • NYX-2925

今後的活動

成功的可能性

本源專利

商機

臨床試驗環境

  • 贊助商:各進展狀況
  • 贊助商:各階段

文獻

  • 處方資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0206383

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, patent information, and prevalence data, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The approved drugs in the fibromyalgia space target dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, serotonin reuptake, and voltage-gated calcium channels. All of the marketed drugs for fibromyalgia are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for fibromyalgia are in Phase II, with two drugs in Phase III.

Therapies in development for fibromyalgia focus on a wide variety of targets. These drugs are most commonly administered via the oral route.

The only high-impact upcoming event in the fibromyalgia space is topline Phase IIa trial results for ASP0819. The overall likelihood of approval of a Phase I pain asset is 7.2%, and the average probability a drug advances from Phase III is 58.6%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for fibromyalgia have been in the late phases of development, with 68% of trials in Phase III-IV, and 32% in Phase I-II.

The US has a substantial lead in the number of fibromyalgia clinical trials globally. Germany, Spain, and the UK lead the major EU markets, while India has the top spot in Asia.

Clinical trial activity in the fibromyalgia space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for fibromyalgia, with 23 trials.

Pfizer leads industry sponsors with the highest overall number of clinical trials for fibromyalgia, followed by Allergan.

TABLE OF CONTENTS

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

7 Disease definition

7 Symptoms

7 Patient subtypes

8 Risk factors

8 Diagnosis

10 TREATMENT

10 Pharmacologic therapies

12 EPIDEMIOLOGY

12 Fibromyalgia prevalence

13 MARKETED DRUGS

15 PIPELINE DRUGS

21 RECENT EVENTS AND ANALYST OPINION

21 Multiple Drugs for Fibromyalgia (June 25, 2019)

21 NYX-2925 for Fibromyalgia (June 10, 2019)

23 NYX-2925 for Fibromyalgia (December 3, 2018)

26 KEY UPCOMING EVENTS

27 PROBABILITY OF SUCCESS

28 PARENT PATENTS

29 REVENUE OPPORTUNITY

30 CLINICAL TRIAL LANDSCAPE

31 Sponsors by status

32 Sponsors by phase

34 BIBLIOGRAPHY

34 Prescription information

36 APPENDIX

LIST OF FIGURES

  • 15 Figure 1: Overview of pipeline drugs for fibromyalgia in the US
  • 16 Figure 2: Pipeline drugs for fibromyalgia, by company
  • 16 Figure 3: Pipeline drugs for fibromyalgia, by drug type
  • 16 Figure 4: Pipeline drugs for fibromyalgia, by classification
  • 23 Figure 5: NYX-2925 for Fibromyalgia (June 10, 2019): Phase II - Pilot Study
  • 25 Figure 6: NYX-2925 for Fibromyalgia (December 3, 2018): Phase II - Pilot Study
  • 26 Figure 7: Key upcoming events in fibromyalgia
  • 27 Figure 8: Probability of success in the fibromyalgia pipeline
  • 28 Figure 9: Parent patents in fibromyalgia
  • 30 Figure 10: Clinical trials in fibromyalgia
  • 30 Figure 11: Top 10 drugs for clinical trials in fibromyalgia
  • 31 Figure 12: Top 10 companies for clinical trials in fibromyalgia
  • 31 Figure 13: Trial locations in fibromyalgia
  • 32 Figure 14: Fibromyalgia trials status
  • 33 Figure 15: Fibromyalgia trials sponsors, by phase

LIST OF TABLES

  • 14 Table 1: Marketed drugs for fibromyalgia
  • 18 Table 2: Pipeline drugs for fibromyalgia in the US
  • 21 Table 3: Multiple Drugs for Fibromyalgia (June 25, 2019)
  • 22 Table 4: NYX-2925 for Fibromyalgia (June 10, 2019)
  • 24 Table 5: NYX-2925 for Fibromyalgia (December 3, 2018)
  • 29 Table 6: Historical global sales, by drug ($m), 2014-18
  • 29 Table 7: Forecasted global sales, by drug ($m), 2019-23